- Home
- DARE vs GSIW Comparison
DARE vs GSIW Comparison
Compare DARE & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- GSIW
- Stock Information
- Founded
- DARE 2015
- GSIW 2016
- Country
- DARE United States
- GSIW Hong Kong
- Employees
- DARE N/A
- GSIW N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- DARE Health Care
- GSIW
- Exchange
- DARE Nasdaq
- GSIW Nasdaq
- Market Cap
- DARE 26.3M
- GSIW 27.2M
- IPO Year
- DARE N/A
- GSIW 2023
- Fundamental
- Price
- DARE $2.40
- GSIW $1.60
- Analyst Decision
- DARE Strong Buy
- GSIW
- Analyst Count
- DARE 3
- GSIW 0
- Target Price
- DARE $12.50
- GSIW N/A
- AVG Volume (30 Days)
- DARE 38.9K
- GSIW 2.2M
- Earning Date
- DARE 08-11-2025
- GSIW 01-01-0001
- Dividend Yield
- DARE N/A
- GSIW N/A
- EPS Growth
- DARE N/A
- GSIW N/A
- EPS
- DARE N/A
- GSIW N/A
- Revenue
- DARE $25,909.00
- GSIW $1,313,795.00
- Revenue This Year
- DARE $99,756.91
- GSIW N/A
- Revenue Next Year
- DARE $119.77
- GSIW N/A
- P/E Ratio
- DARE N/A
- GSIW N/A
- Revenue Growth
- DARE N/A
- GSIW N/A
- 52 Week Low
- DARE $2.35
- GSIW $0.35
- 52 Week High
- DARE $4.60
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- DARE 32.17
- GSIW 74.17
- Support Level
- DARE $2.37
- GSIW $1.48
- Resistance Level
- DARE $2.54
- GSIW $1.64
- Average True Range (ATR)
- DARE 0.11
- GSIW 0.12
- MACD
- DARE -0.02
- GSIW -0.02
- Stochastic Oscillator
- DARE 8.32
- GSIW 77.78
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.